Rachel E. Thomson

1.4k total citations
16 papers, 902 citations indexed

About

Rachel E. Thomson is a scholar working on Molecular Biology, Physiology and Genetics. According to data from OpenAlex, Rachel E. Thomson has authored 16 papers receiving a total of 902 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 5 papers in Physiology and 5 papers in Genetics. Recurrent topics in Rachel E. Thomson's work include Muscle Physiology and Disorders (8 papers), Epigenetics and DNA Methylation (5 papers) and Fibroblast Growth Factor Research (4 papers). Rachel E. Thomson is often cited by papers focused on Muscle Physiology and Disorders (8 papers), Epigenetics and DNA Methylation (5 papers) and Fibroblast Growth Factor Research (4 papers). Rachel E. Thomson collaborates with scholars based in United States, Australia and United Kingdom. Rachel E. Thomson's co-authors include Paul Gregorevic, Hongwei Qian, Catherine E. Winbanks, Justin L. Chen, Craig A. Harrison, Claudia Beyer, Julie R. McMullen, Tomoko Iwata, Gordon S. Lynch and Patricio V. Sepulveda and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Cell Biology and Scientific Reports.

In The Last Decade

Rachel E. Thomson

16 papers receiving 891 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rachel E. Thomson United States 12 704 287 152 138 92 16 902
Marshall W. Hogarth United States 14 649 0.9× 220 0.8× 206 1.4× 139 1.0× 94 1.0× 18 885
Jun Tanihata Japan 17 700 1.0× 166 0.6× 112 0.7× 69 0.5× 89 1.0× 40 906
Timur Naim Australia 17 759 1.1× 453 1.6× 54 0.4× 172 1.2× 58 0.6× 36 960
Marc A. Egerman United States 7 689 1.0× 414 1.4× 52 0.3× 167 1.2× 86 0.9× 9 963
Stefania Assereto Italy 17 563 0.8× 105 0.4× 149 1.0× 138 1.0× 40 0.4× 24 791
Alfredo Csibi France 10 858 1.2× 362 1.3× 63 0.4× 249 1.8× 53 0.6× 12 1.1k
Enrico Bertaggia Italy 10 676 1.0× 337 1.2× 45 0.3× 190 1.4× 54 0.6× 11 1.1k
Scott D. Dufresne United States 17 903 1.3× 562 2.0× 119 0.8× 282 2.0× 84 0.9× 22 1.4k
Kevin I. Watt Australia 12 854 1.2× 288 1.0× 78 0.5× 312 2.3× 55 0.6× 19 1.2k
Ermelinda Ceco United States 10 479 0.7× 136 0.5× 67 0.4× 54 0.4× 92 1.0× 11 655

Countries citing papers authored by Rachel E. Thomson

Since Specialization
Citations

This map shows the geographic impact of Rachel E. Thomson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel E. Thomson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel E. Thomson more than expected).

Fields of papers citing papers by Rachel E. Thomson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel E. Thomson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel E. Thomson. The network helps show where Rachel E. Thomson may publish in the future.

Co-authorship network of co-authors of Rachel E. Thomson

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel E. Thomson. A scholar is included among the top collaborators of Rachel E. Thomson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel E. Thomson. Rachel E. Thomson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Thomson, Rachel E., et al.. (2024). Striated muscle: an inadequate soil for cancers. Cancer and Metastasis Reviews. 43(4). 1511–1527. 3 indexed citations
2.
Hagg, Adam, Craig A. Goodman, Justin L. Chen, et al.. (2020). TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass. Frontiers in Physiology. 11. 560225–560225. 7 indexed citations
3.
Davey, Jonathan R., Emma Estévez, Rachel E. Thomson, et al.. (2020). Intravascular Follistatin gene delivery improves glycemic control in a mouse model of type 2 diabetes. The FASEB Journal. 34(4). 5697–5714. 12 indexed citations
4.
Hagg, Adam, et al.. (2016). Using AAV vectors expressing the β2-adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size. Scientific Reports. 6(1). 23042–23042. 16 indexed citations
5.
Winbanks, Catherine E., Kate T. Murphy, Bianca C. Bernardo, et al.. (2016). Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Science Translational Medicine. 8(348). 348ra98–348ra98. 70 indexed citations
6.
Sepulveda, Patricio V., Séverine Lamon, Adam Hagg, et al.. (2015). Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy. Scientific Reports. 5(1). 17535–17535. 33 indexed citations
7.
Winbanks, Catherine E., Justin L. Chen, Hongwei Qian, et al.. (2013). The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. The Journal of Cell Biology. 203(2). 345–357. 168 indexed citations
8.
Winbanks, Catherine E., Justin L. Chen, Hongwei Qian, et al.. (2013). The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. The Journal of Experimental Medicine. 210(12). 21012OIA54–21012OIA54. 6 indexed citations
9.
Chen, Justin L., Kelly L. Walton, Catherine E. Winbanks, et al.. (2013). Elevated expression of activins promotes muscle wasting and cachexia. The FASEB Journal. 28(4). 1711–1723. 155 indexed citations
10.
Winbanks, Catherine E., Kate L. Weeks, Rachel E. Thomson, et al.. (2012). Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. The Journal of Cell Biology. 197(7). 997–1008. 179 indexed citations
11.
Pellicano, Francesca, Rachel E. Thomson, Gareth J. Inman, & Tomoko Iwata. (2010). Regulation of cell proliferation and apoptosis in neuroblastoma cells by ccp1, a FGF2 downstream gene. BMC Cancer. 10(1). 657–657. 9 indexed citations
12.
Thomson, Rachel E., Peter C. Kind, Nicholas Graham, et al.. (2009). Fgf receptor 3 activation promotes selective growth and expansion of occipitotemporal cortex. Neural Development. 4(1). 4–4. 52 indexed citations
13.
Thomson, Rachel E., Francesca Pellicano, & Tomoko Iwata. (2006). Fibroblast growth factor receptor 3 kinase domain mutation increases cortical progenitor proliferation via mitogen‐activated protein kinase activation. Journal of Neurochemistry. 100(6). 1565–1578. 29 indexed citations
14.
Broadgate, Suzanne, Rachel E. Thomson, Francesca Pellicano, et al.. (2005). FGFR3 regulates brain size by controlling progenitor cell proliferation and apoptosis during embryonic development. Developmental Biology. 279(1). 73–85. 66 indexed citations
15.
Thomson, Rachel E., Alison Bigley, John R. Foster, et al.. (2004). Tissue-specific Expression and Subcellular Distribution of Murine Glutathione S-transferase Class Kappa. Journal of Histochemistry & Cytochemistry. 52(5). 653–662. 43 indexed citations
16.
Jowsey, Ian R., Rachel E. Thomson, Terry C. Orton, Clifford R. Elcombe, & John D. Hayes. (2003). Biochemical and genetic characterization of a murine class Kappa glutathione S-transferase. Biochemical Journal. 373(2). 559–569. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026